Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.09
CVS's Cash to Debt is ranked higher than
70% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. CVS: 0.09 )
CVS' s 10-Year Cash to Debt Range
Min: 0.06   Max: 1.14
Current: 0.09

0.06
1.14
Equity to Asset 0.52
CVS's Equity to Asset is ranked higher than
78% of the 302 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. CVS: 0.52 )
CVS' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.67
Current: 0.52

0.39
0.67
Interest Coverage 15.55
CVS's Interest Coverage is ranked higher than
83% of the 183 Companies
in the Global Medical Care industry.

( Industry Median: 4.80 vs. CVS: 15.55 )
CVS' s 10-Year Interest Coverage Range
Min: 3.46   Max: 29.6
Current: 15.55

3.46
29.6
F-Score: 5
Z-Score: 4.82
M-Score: -2.36
WACC vs ROIC
8.90%
10.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.43
CVS's Operating margin (%) is ranked higher than
70% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 9.26 vs. CVS: 6.43 )
CVS' s 10-Year Operating margin (%) Range
Min: 3.46   Max: 6.91
Current: 6.43

3.46
6.91
Net-margin (%) 3.39
CVS's Net-margin (%) is ranked higher than
72% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 4.62 vs. CVS: 3.39 )
CVS' s 10-Year Net-margin (%) Range
Min: -5.87   Max: 3.76
Current: 3.39

-5.87
3.76
ROE (%) 12.02
CVS's ROE (%) is ranked higher than
83% of the 287 Companies
in the Global Medical Care industry.

( Industry Median: 7.86 vs. CVS: 12.02 )
CVS' s 10-Year ROE (%) Range
Min: 3.69   Max: 18.7
Current: 12.02

3.69
18.7
ROA (%) 6.40
CVS's ROA (%) is ranked higher than
85% of the 305 Companies
in the Global Medical Care industry.

( Industry Median: 3.18 vs. CVS: 6.40 )
CVS' s 10-Year ROA (%) Range
Min: 1.52   Max: 9.8
Current: 6.4

1.52
9.8
ROC (Joel Greenblatt) (%) 57.14
CVS's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 13.15 vs. CVS: 57.14 )
CVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 18.78   Max: 63.66
Current: 57.14

18.78
63.66
Revenue Growth (3Y)(%) 14.10
CVS's Revenue Growth (3Y)(%) is ranked higher than
90% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. CVS: 14.10 )
CVS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 7.7   Max: 16
Current: 14.1

7.7
16
EBITDA Growth (3Y)(%) 13.60
CVS's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 190 Companies
in the Global Medical Care industry.

( Industry Median: 6.40 vs. CVS: 13.60 )
CVS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 2.4   Max: 44
Current: 13.6

2.4
44
EPS Growth (3Y)(%) 14.60
CVS's EPS Growth (3Y)(%) is ranked higher than
81% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 9.50 vs. CVS: 14.60 )
CVS' s 10-Year EPS Growth (3Y)(%) Range
Min: 1.4   Max: 109.5
Current: 14.6

1.4
109.5
» CVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CVS Guru Trades in Q1 2014

Robert Olstein 92,000 sh (New)
Tom Gayner 96,000 sh (New)
PRIMECAP Management 3,221,930 sh (+521.24%)
Joel Greenblatt 7,622 sh (+77.75%)
Ruane Cunniff 27,049 sh (+6.27%)
Pioneer Investments 4,513,000 sh (+2.05%)
Jeff Auxier 98,799 sh (+0.33%)
First Pacific Advisors 7,470,700 sh (+0.26%)
Charles de Vaulx 899,866 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
RS Investment Management 604,025 sh (unchged)
John Rogers 98,420 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
Vanguard Health Care Fund 4,388,100 sh (unchged)
Wallace Weitz Sold Out
Scott Black 178,556 sh (-1.15%)
Steven Cohen 60,850 sh (-1.78%)
Mario Gabelli 1,568,681 sh (-1.98%)
NWQ Managers 2,744,031 sh (-7.26%)
James Barrow 294,395 sh (-18.47%)
Signature Select Canadian Fund 126,053 sh (-33.85%)
Ken Fisher 88,108 sh (-44.33%)
Jeremy Grantham 1,649,081 sh (-50.71%)
Bill Frels 3,367 sh (-51.81%)
Chris Davis 11,435,259 sh (-65.41%)
» More
Q2 2014

CVS Guru Trades in Q2 2014

Louis Moore Bacon 5,316 sh (New)
Paul Tudor Jones 5,542 sh (New)
Manning & Napier Advisors, Inc 133,150 sh (New)
Joel Greenblatt 65,796 sh (+763.24%)
Tom Gayner 197,000 sh (+105.21%)
Ken Fisher 155,365 sh (+76.33%)
James Barrow 348,795 sh (+18.48%)
Bill Frels 3,402 sh (+1.04%)
RS Investment Management 607,225 sh (+0.53%)
First Pacific Advisors 7,497,100 sh (+0.35%)
Robert Olstein 92,000 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
Vanguard Health Care Fund 4,388,100 sh (unchged)
Charles de Vaulx 899,866 sh (unchged)
Caxton Associates 100,000 sh (unchged)
John Rogers 98,420 sh (unchged)
Ruane Cunniff 27,028 sh (-0.08%)
Mario Gabelli 1,563,642 sh (-0.32%)
Jeff Auxier 98,449 sh (-0.35%)
PRIMECAP Management 3,206,070 sh (-0.49%)
Pioneer Investments 4,287,706 sh (-4.99%)
Chris Davis 9,012,151 sh (-21.19%)
NWQ Managers 2,118,767 sh (-22.79%)
Scott Black 126,558 sh (-29.12%)
Jeremy Grantham 109,100 sh (-93.38%)
» More
Q3 2014

CVS Guru Trades in Q3 2014

Steven Cohen 60,300 sh (New)
Jeremy Grantham 347,800 sh (+218.79%)
Bill Frels 4,243 sh (+24.72%)
Tom Gayner 218,000 sh (+10.66%)
James Barrow 359,133 sh (+2.96%)
Charles de Vaulx 913,605 sh (+1.53%)
First Pacific Advisors 7,565,900 sh (+0.92%)
Pioneer Investments 5,372,599 sh (unchged)
Vanguard Health Care Fund 4,388,100 sh (unchged)
Robert Olstein 92,000 sh (unchged)
Steven Romick 6,805,000 sh (unchged)
Westport Asset Management 192,090 sh (unchged)
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
PRIMECAP Management 3,198,460 sh (-0.24%)
Jeff Auxier 98,124 sh (-0.33%)
Scott Black 124,326 sh (-1.76%)
Ruane Cunniff 26,553 sh (-1.76%)
Mario Gabelli 1,528,010 sh (-2.28%)
John Rogers 95,275 sh (-3.2%)
NWQ Managers 1,939,169 sh (-8.48%)
RS Investment Management 552,150 sh (-9.07%)
Manning & Napier Advisors, Inc 120,770 sh (-9.3%)
Ken Fisher 140,754 sh (-9.4%)
Signature Select Canadian Fund 99,853 sh (-20.78%)
Chris Davis 2,153,905 sh (-76.1%)
Joel Greenblatt 9,348 sh (-85.79%)
» More
Q4 2014

CVS Guru Trades in Q4 2014

Ray Dalio 55,411 sh (New)
Paul Tudor Jones 11,847 sh (New)
Tom Gayner 232,000 sh (+6.42%)
Manning & Napier Advisors, Inc 125,196 sh (+3.66%)
Pioneer Investments 5,496,034 sh (+2.3%)
Ken Fisher 142,036 sh (+0.91%)
Charles de Vaulx 915,821 sh (+0.24%)
Westport Asset Management 192,090 sh (unchged)
Chris Davis Sold Out
Steven Cohen Sold Out
Jeff Auxier 97,799 sh (-0.33%)
PRIMECAP Management 3,186,930 sh (-0.36%)
John Rogers 93,675 sh (-1.68%)
James Barrow 352,989 sh (-1.71%)
Mario Gabelli 1,489,263 sh (-2.54%)
Ruane Cunniff 24,953 sh (-6.03%)
Vanguard Health Care Fund 4,015,136 sh (-8.5%)
Steven Romick 6,220,000 sh (-8.6%)
First Pacific Advisors 6,885,500 sh (-8.99%)
RS Investment Management 496,750 sh (-10.03%)
Bill Frels 3,731 sh (-12.07%)
Scott Black 108,124 sh (-13.03%)
Robert Olstein 75,000 sh (-18.48%)
NWQ Managers 1,287,296 sh (-33.62%)
Jeremy Grantham 226,300 sh (-34.93%)
Joel Greenblatt 5,154 sh (-44.87%)
» More
» Details

Insider Trades

Latest Guru Trades with CVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
NWQ Managers 2014-12-31 Reduce -33.62%0.57%$78.81 - $98.25 $ 103.4517%1287296
Chris Davis 2014-12-31 Sold Out 0.53%$78.81 - $98.25 $ 103.4517%0
Scott Black 2014-12-31 Reduce -13.03%0.18%$78.81 - $98.25 $ 103.4517%108124
Robert Olstein 2014-12-31 Reduce -18.48%0.18%$78.81 - $98.25 $ 103.4517%75000
Ray Dalio 2014-12-31 New Buy0.04%$78.81 - $98.25 $ 103.4517%55411
Joel Greenblatt 2014-12-31 Reduce -44.87%$78.81 - $98.25 $ 103.4517%5154
Chris Davis 2014-09-30 Reduce -76.1%1.52%$76.11 - $82.24 $ 103.4531%2153905
NWQ Managers 2014-09-30 Reduce -8.48%0.14%$76.11 - $82.24 $ 103.4531%1939169
Joel Greenblatt 2014-09-30 Reduce -85.79%0.05%$76.11 - $82.24 $ 103.4531%9348
Chris Davis 2014-06-30 Reduce -21.19%0.51%$72.58 - $78.92 $ 103.4537%9012151
NWQ Managers 2014-06-30 Reduce -22.79%0.41%$72.58 - $78.92 $ 103.4537%2118767
Scott Black 2014-06-30 Reduce -29.12%0.41%$72.58 - $78.92 $ 103.4537%126558
Tom Gayner 2014-06-30 Add 105.21%0.22%$72.58 - $78.92 $ 103.4537%197000
Joel Greenblatt 2014-06-30 Add 763.24%0.05%$72.58 - $78.92 $ 103.4537%65796
Ken Fisher 2014-06-30 Add 76.33%0.01%$72.58 - $78.92 $ 103.4537%155365
Chris Davis 2014-03-31 Reduce -65.41%3.79%$65.44 - $75.3 $ 103.4546%11435259
Robert Olstein 2014-03-31 New Buy0.94%$65.44 - $75.3 $ 103.4546%92000
PRIMECAP Management 2014-03-31 Add 521.24%0.23%$65.44 - $75.3 $ 103.4546%3221930
Tom Gayner 2014-03-31 New Buy0.22%$65.44 - $75.3 $ 103.4546%96000
NWQ Managers 2014-03-31 Reduce -7.26%0.14%$65.44 - $75.3 $ 103.4546%2744031
Wallace Weitz 2014-03-31 Sold Out 0.02%$65.44 - $75.3 $ 103.4546%0
Ken Fisher 2014-03-31 Reduce -44.33%0.01%$65.44 - $75.3 $ 103.4547%88108
Joel Greenblatt 2014-03-31 Add 77.75%$65.44 - $75.3 $ 103.4546%7622
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on CVS Health Corp

Mario Gabelli Comments on CVS Health Corp - Oct 29, 2014

CVS Health Corp. (1.6%) (CVS - $79.59 - NYSE) operates one of the largest retail pharmacy chains in the country, and the company is poised to benefit from the expansion of insurance coverage under healthcare reform with no new taxes or regulation. CVS is expanding into the fast growing market for specialty and biotech medicines, particularly through the recently announced $2 billion acquisition of home infusion provider Coram. CVS Health recently stopped selling tobacco in its stores, but the company is performing so strongly this year that it can easily absorb the $2 billion in lost sales. The company can sustain double digit earnings growth, and management continues to return a substantial amount of cash to shareholders via a higher dividend and share repurchases.

From Mario Gabelli (Trades, Portfolio)’s Equity Income Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades

Jeff Auxier Comments on CVS - Feb 13, 2014

Healthcare stocks in the Fund had a strong fourth quarter and year. CVS (CVS)’s 26% performance for the quarter is reflective of the fact that 10,000 Americans turn 65 every day and will for the next 15 years. Businesses that are able to serve this growing segment with improving service, innovation, technology, product quality and value should continue to win.



From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2013 commentary.

Check out Jeff Auxier latest stock trades

Top Ranked Articles about CVS Health Corp

Oakmark Equity and Income Fund Fourth Quarter 2014 Commentary
Another strong December, quarter and year Read more...
Mario Gabelli Comments on CVS Health Corp
CVS Health Corp. (1.6%) (CVS - $79.59 - NYSE) operates one of the largest retail pharmacy chains in the country, and the company is poised to benefit from the expansion of insurance coverage under healthcare reform with no new taxes or regulation. CVS is expanding into the fast growing market for specialty and biotech medicines, particularly through the recently announced $2 billion acquisition of home infusion provider Coram. CVS Health recently stopped selling tobacco in its stores, but the company is performing so strongly this year that it can easily absorb the $2 billion in lost sales. The company can sustain double digit earnings growth, and management continues to return a substantial amount of cash to shareholders via a higher dividend and share repurchases. Read more...
The Olstein All Cap Value Fund’s 2014 First Quarter Letter to Shareholders
Dear Fellow Shareholders: Read more...
NEW SITE FEATURE: 10-Year Median Scans
GuruFocus has always delievered the most vast offering of equity research tools available on the market. Last year we introduced the All-In-One Guru Screener. It has been met with immensely positive feedback and has quickly become the go-to scanner for sophisticated investors. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 26.60
CVS's P/E(ttm) is ranked higher than
85% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 43.30 vs. CVS: 26.60 )
CVS' s 10-Year P/E(ttm) Range
Min: 10.57   Max: 26.94
Current: 26.6

10.57
26.94
Forward P/E 17.64
CVS's Forward P/E is ranked higher than
87% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 26.67 vs. CVS: 17.64 )
N/A
PE(NRI) 26.90
CVS's PE(NRI) is ranked higher than
85% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 40.70 vs. CVS: 26.90 )
CVS' s 10-Year PE(NRI) Range
Min: 10.58   Max: 26.92
Current: 26.9

10.58
26.92
P/B 3.10
CVS's P/B is ranked higher than
74% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 3.14 vs. CVS: 3.10 )
CVS' s 10-Year P/B Range
Min: 1.01   Max: 3.37
Current: 3.1

1.01
3.37
P/S 0.90
CVS's P/S is ranked higher than
82% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 1.73 vs. CVS: 0.90 )
CVS' s 10-Year P/S Range
Min: 0.4   Max: 0.91
Current: 0.9

0.4
0.91
PFCF 29.40
CVS's PFCF is ranked higher than
84% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 47.64 vs. CVS: 29.40 )
CVS' s 10-Year PFCF Range
Min: 9.1   Max: 208.79
Current: 29.4

9.1
208.79
POCF 19.73
CVS's POCF is ranked higher than
78% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 16.94 vs. CVS: 19.73 )
CVS' s 10-Year POCF Range
Min: 6.73   Max: 35.81
Current: 19.73

6.73
35.81
EV-to-EBIT 14.34
CVS's EV-to-EBIT is ranked higher than
86% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 23.61 vs. CVS: 14.34 )
CVS' s 10-Year EV-to-EBIT Range
Min: 7.6   Max: 20.4
Current: 14.34

7.6
20.4
PEG 2.86
CVS's PEG is ranked higher than
94% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. CVS: 2.86 )
CVS' s 10-Year PEG Range
Min: 0.56   Max: 7.32
Current: 2.86

0.56
7.32
Shiller P/E 33.20
CVS's Shiller P/E is ranked higher than
85% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 207.68 vs. CVS: 33.20 )
CVS' s 10-Year Shiller P/E Range
Min: 13.82   Max: 33.29
Current: 33.2

13.82
33.29
Current Ratio 1.39
CVS's Current Ratio is ranked higher than
74% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. CVS: 1.39 )
CVS' s 10-Year Current Ratio Range
Min: 1.05   Max: 2.09
Current: 1.39

1.05
2.09
Quick Ratio 0.75
CVS's Quick Ratio is ranked higher than
59% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. CVS: 0.75 )
CVS' s 10-Year Quick Ratio Range
Min: 0.2   Max: 0.93
Current: 0.75

0.2
0.93
Days Inventory 37.16
CVS's Days Inventory is ranked higher than
77% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 71.27 vs. CVS: 37.16 )
CVS' s 10-Year Days Inventory Range
Min: 38.23   Max: 99.44
Current: 37.16

38.23
99.44
Days Sales Outstanding 29.24
CVS's Days Sales Outstanding is ranked higher than
90% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 52.71 vs. CVS: 29.24 )
CVS' s 10-Year Days Sales Outstanding Range
Min: 10.82   Max: 25.13
Current: 29.24

10.82
25.13

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.10
CVS's Dividend Yield is ranked lower than
63% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 1.45 vs. CVS: 1.10 )
CVS' s 10-Year Dividend Yield Range
Min: 0.42   Max: 1.47
Current: 1.1

0.42
1.47
Dividend Payout 0.28
CVS's Dividend Payout is ranked higher than
89% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. CVS: 0.28 )
CVS' s 10-Year Dividend Payout Range
Min: 0.08   Max: 1.87
Current: 0.28

0.08
1.87
Dividend growth (3y) 37.00
CVS's Dividend growth (3y) is ranked higher than
94% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 11.00 vs. CVS: 37.00 )
CVS' s 10-Year Dividend growth (3y) Range
Min: -33.3   Max: 37
Current: 37

-33.3
37
Yield on cost (5-Year) 3.91
CVS's Yield on cost (5-Year) is ranked higher than
80% of the 189 Companies
in the Global Medical Care industry.

( Industry Median: 1.85 vs. CVS: 3.91 )
CVS' s 10-Year Yield on cost (5-Year) Range
Min: 1.49   Max: 5.23
Current: 3.91

1.49
5.23
Share Buyback Rate 3.80
CVS's Share Buyback Rate is ranked higher than
94% of the 192 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. CVS: 3.80 )
CVS' s 10-Year Share Buyback Rate Range
Min: 4.1   Max: -20.4
Current: 3.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1149.40
CVS's Price/Tangible Book is ranked higher than
68% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 22.44 vs. CVS: 1149.40 )
CVS' s 10-Year Price/Tangible Book Range
Min: 2.07   Max: 2407.75
Current: 1149.4

2.07
2407.75
Price/DCF (Projected) 1.50
CVS's Price/DCF (Projected) is ranked higher than
85% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 3.93 vs. CVS: 1.50 )
CVS' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 13.56
Current: 1.5

0.82
13.56
Price/Median PS Value 1.50
CVS's Price/Median PS Value is ranked higher than
66% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 1.31 vs. CVS: 1.50 )
CVS' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 2.48
Current: 1.5

0.45
2.48
Price/Peter Lynch Fair Value 2.20
CVS's Price/Peter Lynch Fair Value is ranked higher than
93% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. CVS: 2.20 )
CVS' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.63   Max: 3.68
Current: 2.2

0.63
3.68
Price/Graham Number 37.30
CVS's Price/Graham Number is ranked higher than
77% of the 329 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. CVS: 37.30 )
CVS' s 10-Year Price/Graham Number Range
Min: 1.13   Max: 29.02
Current: 37.3

1.13
29.02
Earnings Yield (Greenblatt) 7.00
CVS's Earnings Yield (Greenblatt) is ranked higher than
85% of the 304 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. CVS: 7.00 )
CVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.9   Max: 13.1
Current: 7

4.9
13.1
Forward Rate of Return (Yacktman) 14.82
CVS's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 9.87 vs. CVS: 14.82 )
CVS' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 24.2
Current: 14.82

2.9
24.2

Business Description

Industry: Health Care Providers » Medical Care
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:CVS.Germany, CVS.Mexico, CVS.Chile,
CVS Health Corp, formerly known as CVS Caremark Corporation was incorporated in the State of Delaware. The Company is an integrated pharmacy health care provider in the United States. They manage pharmaceutical costs and improve health care outcomes through their pharmacy benefit management ("PBM"), mail order and specialty pharmacy division, CVS Caremark Pharmacy Services; our more than 7,600 CVS/pharmacy, Longs Drugs and Drogaria Onofre retail stores; our retail-based health clinic subsidiary, MinuteClinic; and our online retail pharmacies, CVS.com and Onofre.com.br. They have three segments: Pharmacy Services, Retail Pharmacy and Corporate. The pharmacy services segment provides a full range of PBM services, as described more fully below, to their clients consisting primarily of employers, insurance companies, unions, government employee groups, managed care organizations ("MCOs") and other sponsors of health benefit plans and individuals throughout the United States. They operate four mail service dispensing pharmacies in the United States. They also operate a network of smaller mail service specialty pharmacies. There specialty pharmacies support individuals that require complex and expensive drug therapies. There specialty pharmacies were comprised of 11 specialty mail order pharmacies located throughout the United States that are used for delivery of advanced medications to individuals with chronic or genetic diseases and disorders. Substantially all of these pharmacies have been accredited by the Joint Commission, which is an independent, not-for-profit organization that accredits and certifies more than 20,000 health care organizations and programs in the United States. The retail pharmacy segment included 7,660 retail drugstores, of which 7,603 operated a pharmacy, their online retail pharmacy websites, CVS.com and Onofre.com.br, 17 onsite pharmacy stores and our retail health care clinics. There corporate segment provides management and administrative services to support the overall operations of the company. The corporate Segment consists of certain aspects of our executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance departments. The Company's business is subject to federal and state laws and regulations that govern the purchase, sale and distribution of prescription drugs and related services, including administration and management of prescription drug benefits.
» More Articles for CVS

Headlines

Articles On GuruFocus.com
Gabelli Growth Fund Q4 Commentary Feb 24 2015 
Looking Ahead of Wall Street: Coca-Cola, PepsiCo, CVS Health Feb 09 2015 
Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 
Has Gilead Sciences Been Able To Maintain Its Lead Run In The Face Of Competition? Jan 22 2015 
18 Cool Dividend Growth Large Caps For A Hot Market Jan 14 2015 
Weekly Insider Sells Highlight: CVS, MNST, CAG, EVHC Jan 11 2015 
Weekly CEO Sells Highlight: Six Flags Entertainment Corp, Gilead Sciences Inc, Ingersoll-Rand PLC, C Jan 10 2015 
Oakmark Equity and Income Fund Fourth Quarter 2014 Commentary Jan 09 2015 
Gilead Strikes Deal with CVS, Hits Back AbbVie Jan 06 2015 
Why Ballard Power Systems Is a Smart Investment Dec 19 2014 


More From Other Websites
Final Glance: Drug Benefits companies Mar 03 2015
Final Glance: Drugstore companies Mar 03 2015
Final Glance: Drugstore companies Mar 03 2015
Final Glance: Drug Benefits companies Mar 03 2015
Cardinal Health Set to Buy Cordis, Shares Hit 52-Week High - Analyst Blog Mar 03 2015
Midday Glance: Drugstore companies Mar 02 2015
Midday Glance: Drugstore companies Mar 02 2015
Midday Glance: Drug Benefits companies Mar 02 2015
Midday Glance: Drug Benefits companies Mar 02 2015
Early Glance: Drugstore companies Mar 02 2015
Early Glance: Drugstore companies Mar 02 2015
Early Glance: Drug Benefits companies Mar 02 2015
Early Glance: Drug Benefits companies Mar 02 2015
Campus Crest Communities Inc (CCG): Clinton Group Goes Activist; Check Out the Fund’s Other Top... Mar 02 2015
CVS Health To Present At Barclays Global Healthcare Conference Feb 27 2015
CVS Health To Present At Barclays Global Healthcare Conference Feb 27 2015
Horizon Pharma Soars On Q4 Beat, Guidance Raise Feb 27 2015
Catamaran EPS Tops, But Stock Falls On Weak Guidance Feb 26 2015
Moody's Upgrades Three and Affirms Three Classes of FULB 1998-C2 Feb 26 2015
Apple has Apple Pay hurdles to jump Feb 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK